AVR · Anteris Technologies Global Corp.

Current Thesis

Clinical-stage structural-heart disruptor (dual-listed ASX/NASDAQ) whose DurAVR THV a single-piece, 3D-shaped biomimetic transcatheter aortic valve is now in its US pivotal PARADIGM trial. The narrative de-risked on a tight milestone sequence: CMS national Coverage-with-Evidence-Development (NCD 20.32) approved 2026-04-28, first US patients treated 2026-05-05 at Montefiore (Dr. Azeem Latib), Medtronic strategic stake taken in the January raise, Barclays Overweight PT $18. That flow drove a +448% YoY run. The week-over-week change matters: last week the stock was pinned on the $9.00 TD Cowen ATM reference ($8.95 close 6/3); it has since broken above that level, closed $9.64 on 2026-06-05, and printed a fresh 52-week high of $10.14. Structurally the offer price flipped from ceiling to reclaimed pivot. But the breakout is running on momentum into a live $250M seller, with no scheduled catalyst in the next 30 days and the actual binary PARADIGM 1-year primary-endpoint data sitting ~2028 (enrollment completes ~Q1 2027). Real disruptor, improving chart, wrong moment for size: the narrative engine has gone quiet even as price makes highs. MATURING.

Bull Case

• Pivotal trial live and US-enrolling first US patients treated 2026-05-05 (Montefiore, Dr. Latib); PARADIGM is ~1,000 pts, 1:1 randomized DurAVR vs commercial TAVR, non-inferiority composite (all-cause mortality + all stroke + CV hospitalization) at 1yr. FDA IDE secured Q4 2025; enrollment progressing across Europe and the US.
• Reimbursement de-risked early CMS Coverage-with-Evidence-Development under NCD 20.32 approved 2026-04-28; US site activation and enrollment commenced within a week. Removes the largest US trial-execution risk.
• Strategic validation from the incumbent Covidien (a Medtronic subsidiary) committed up to $90M for 16–19.99% of post-offering shares at the offer price; closed 2026-01-22 alongside the $230M public raise ($320M aggregate). An incumbent funding a competing valve is a real signal.
• Sell-side leaning in Barclays Overweight, PT $18 (2026-05-15); Strong Buy consensus, avg PT ~$15.3–$15.5 (~60–80% implied upside from ~$9.6).
• Structure cleared the supply shelf price absorbed the $9.00 ATM level that capped it last week and made a new 52-week high ($10.14, 2026-06-05). Short-term the offer price now sits below market as a reclaimed pivot rather than overhead resistance.
• Funded through enrollment Jan raise plus the $250M ATM facility cover the ~$28.7M/qtr burn with no financing cliff.

Bear Case

• The $250M ATM is now an in-the-money seller. TD Cowen agreement dated 2026-05-22, up to $250M ≈ 26M+ shares (~27% of the 97.3M count) at a 3.0% commission. Above $9 the company can issue directly into the breakout the same facility that creates supply right at the level the chart wants to extend from.
• No catalyst in the window. The last PR was board appointments (Susan Knight, Stephen Denaro) on 2026-05-13. The milestone sequence that drove de-risking (CMS, first patients) is finished; the 1-yr data binary is ~2028. The move to new highs is price-led, not news-led momentum with no fresh narrative fuel.
• Pre-revenue with deep losses 2025 net loss $94.14M on $1.91M revenue (−29% YoY); Q1 2026 net cash outflow $28.7M ($17.5M to R&D), EPS $(0.28) missed by a penny, sales $494K vs $766.67K est. Any clinical hiccup is binary downside on a pure story name.
• Stretched after +448% YoY at $9.64 just under the $10.14 high, reward/risk on a fresh long is poor with a known seller overhead and no near-term repricing event.
• Not a cluster breakout TAVR peers (Edwards Lifesciences EW, Medtronic MDT, Boston Scientific BSX) are mega-caps, not small-cap disruptors breaking out in sympathy. The strength is idiosyncratic, which removes the cluster-confirmation a momentum entry wants.

Setup & Price Structure

• Close 2026-06-05: $9.64 (−0.10% on day). 52-week range $2.85 $10.14. Market cap ~$950M; ~97.34M shares out.
• Week-over-week shift: the $9.00 ATM reference that pinned the tape last week ($8.95 on 6/3) has been reclaimed, and price extended to a fresh high. On the chart this is a breakout above the supply shelf the ATM created.
• The catch: the breakout is on no news into a live ATM. The cleanest way for the offer to get filled is into exactly this strength, which caps the move and risks a round-trip back to/below $9. Distribution-risk continuation, not a confirmed clean breakout.
• Key levels: $9.00 = ATM reference and now-reclaimed pivot a weekly close back below it marks a failed breakout; $10.14 = high to clear and hold; prior base ~$7.50 is the downside structure if $9 fails.

Catalyst Calendar (next 30 days)

• No company-confirmed binary in the window. Enrollment-progress PRs are possible but unscheduled; treat any as incremental, not repricing.
• ASX Appendix 4C quarterly cash report (quarter ending 2026-06-30) due ~2026-07-31 just outside 30 days; watch for ATM-draw pace and burn run-rate.
• Investor-conference appearances (TD Cowen / Barclays healthcare conferences) flagged by the company but dates unconfirmed.
• No earnings in window Q1 reported 2026-05-12; Q2 print ~mid-August.

What Would Change Our Mind

• Weekly close back below $9.00 → breakout failed, ATM reference reasserts as a ceiling, round-trip risk toward the $7.50 base → stand aside.
• Disclosed heavy ATM issuance (8-K / Appendix 4C showing large share sales near these levels) → confirms the seller is capping the move → downgrade / avoid.
• Any PARADIGM safety, mortality, or enrollment-pause signal → binary thesis break on a pre-revenue name.
• Upgrade trigger (the other direction): a weekly hold above $10.14 on rising volume paired with a fresh narrative catalyst (enrollment-pace beat, new analyst initiation, EMA/FDA milestone) would turn this from a LOW probe into a sizeable continuation.

Correlation Notes

• Sits in the structural-heart / TAVR complex against incumbents Edwards Lifesciences (EW), Medtronic (MDT), Boston Scientific (BSX). Medtronic is simultaneously a strategic investor and the incumbent competitor that dual relationship is the one to monitor for either deeper partnership or eventual conflict.
• Dual-listed ASX:AVR / NASDAQ:AVR the ASX session leads the US tape, and material disclosures (Appendix 4C, trial updates) frequently hit before the US open. Watch the Australian announcements feed first.
• Low correlation to broad AI/semis momentum; the driver is idiosyncratic clinical-milestone flow. As a pre-revenue, cash-burning name it carries rate sensitivity a higher-for-longer macro discounts long-dated 2028 data harder.